表紙
市場調査レポート

競合分析:赤血球生成促進剤(ESA)

Competitor Analysis: Erythropoiesis Stimulating Agents (ESA)

発行 La Merie Publishing 商品コード 268446
出版日 ページ情報 英文 94 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
競合分析:赤血球生成促進剤(ESA) Competitor Analysis: Erythropoiesis Stimulating Agents (ESA)
出版日: 2013年04月08日 ページ情報: 英文 94 Pages
概要

当レポートでは、規制市場における従来の第1世代・第2世代エポエチン製品の情報およびエリスロポエチン(EPO)のバイオシミラー版の概要、新・次世代赤血球生成促進剤(ESA)のコンパイル、第1世代EPO製品とダーベポエチンのバイオシミラー版のサマリーなどを提供しており、現在の市販EPO&ESA製品、および研究開発中のEPO&ESAプロジェクト、製品ポートフォリオ別の企業リスト、EPO&ESAのR&Dパイプラインなどをまとめ、概略以下の構成でお届けいたします。

目次

  • 規制市場における第1世代エポエチン
  • 規制市場における第2世代エポエチン
  • 規制市場におけるエポエチンのバイオシミラー
  • 規制市場におけるダーベポエチンのバイオシミラー
  • 規制市場における次世代の生物製剤次世代赤血球生成促進剤(ESA)
  • 次世代の小分子ESA
  • 規制緩和市場における第1世代EPO(中南米;アフリカ;アジア;その他)
  • 規制緩和市場におけるダーベポエチンのバイオシミラー
  • 規制緩和市場における次世代の生物製剤ESA
  • La Merie について
目次
Product Code: LMCA0034

Abstract

Product description

The Competitive Intelligence Report Erythropoiesis Stimulating Agents (ESA) as of April 2013 provides information on existing first and second generation epoetin products in regulated markets, an overview on biosimilar versions of erythropoietin (EPO) in regulated markets, a compilation of novel, next generation Erythropoiesis Stimulating Agents (ESAs) separately for biologics and for oral small molecules and a summary of first generation EPO products as well as of darbepoietin biosimilar versions in less regulated markets.

Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently marketed Erythropoieitin (EPO) & Erythropoiesis Stimulating Agents (ESA) products and active EPO and ESA projects in research and development. In addition, the report lists company-specific product portfolios and R&D pipelines of Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA) on the market or in R&D. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table of Contents

  • First generation epoetins in regulated markets
  • Second generation epoetins in regulated markets
  • Epoetin biosimilars in regulated markets
  • Darbepoetin biosimilars in regulated markets
  • Next generation biologic Eythropoiesis Stimulating Agents (ESA) in regulated markets
  • Next generation small molecule Erythropoiesis Stimulating Agents
  • First generation EPO in less regulated markets (Central & South America; Africa; Asia; Rest of the World)
  • Darbepoietin biosimilars in less regulated markets
  • Next generation biologic Erythropoiesis Stimulating Agents (ESA) in less regulated markets
  • About La Merie
Back to Top